Strategic Partnership To Broaden Anti-Infective Drugs In The Market
PC: Rastudio, Depositphotos
Companies in anti-effective market are active with multiple strategic collaborations and agreements. Top companies in the anti-infective drug market are strategically partnering and collaborating with other companies to broaden their products and services. For instance, in May 2015, Janssen Pharmaceuticals, Inc., subsidiary of Johnson & Johnson has entered into an exclusive worldwide license and collaboration arrangement with Achillion Pharmaceuticals, Inc. to develop and commercialize one or more of Achillion's lead hepatitis C virus (HCV) assets which include ACH-3102, ACH-3422 and sovaprevir. Also in December 2016, Evotec AG was in a strategic alliance with Forge Therapeutics, Inc. to advance its novel Gram-negative antibiotic programme targeting 'LpxC' for the treatment of bacterial infections. Chimerix and ContraVir Pharmaceuticals also entered into a strategic collaboration for antiviral drug candidate CMX157.
ANTI-INFECTIVE DRUGS MARKET TO GROW TO $128 BILLION BY 2020 ACCORDING TO THE BUSINESS RESEARCH COMPANY
The Business Research Company expects the global anti-infective drugs market to grow from $113 billion in 2016 to $128 billion in 2020 at a compound annual growth rate (CAGR) of 3.0%. North America was the largest region in the anti-infective drugs market in 2016, accounting for $35 billion or 30.9% market share. This can be attributed to the presence of established health care networks and high healthcare spending in the region.
Purchase the report at http://www.thebusinessresearchcompany.com/our-research/healthcare/anti-infective-drugs-market-global-briefing-2017/
The chart below shows the year-on-year growth of the global anti-infective drugs market during 2016-2020
According to The Business Research Company’s Healthcare and Biotechnology Consultant, Ravikiran, the demand for new drug candidates for antimicrobial resistant infections is increasing. Antimicrobial resistance is a serious concern to global public health as it resulted in long duration of illness, the requirement of additional tests and use of more expensive drugs. Antimicrobial resistance occurs when microorganisms such as bacteria, viruses, parasites and fungi change and adapted to drugs when they are exposed to antimicrobial drugs such as antibiotics, antivirals, antifungals, anthelmintics and others.
According to World Health Organization (WHO), globally 4,80,000 people are developing multi-drug resistant TB each year and drug resistance is starting to complicate the treatment of malaria and HIV as well. Companies are investing in developing the new drug candidates to treat drug-resistant infections. For instance, in 2014, Cubist Pharmaceuticals launched a new antibiotic Zerbaxa (ceftolozane/tazobactam) for complicated intra-abdominal infections, complicated urinary tract infections and also for infections of the kidney (pyelonephritis). Also, Johnson & Johnson launched Sirturo (bedaquiline) for pulmonary multi-drug resistant tuberculosis. In November 2013, Roche and Polyphor Ltd have entered into a licensing agreement to develop and commercialize Polyphor’s investigational macrocycle antibiotic, POL7080 for the treatment of Pseudomonas aeruginosa bacterial infections which become resistant to many antibiotic treatments.
Request a sample of the report at http://www.thebusinessresearchcompany.com/wp-content/themes/tbrc/sample.php?req=s&title=anti-infective_drugs_market_global_report_2017
Gilead was the largest competitor in the anti-infective drugs market in 2016 with revenues of $16.2 billion in 2016. Gilead’s growth strategy aims to focus on development of products for HIV, viral hepatitis and other diseases through collaborations with other companies, medical research institutions and universities. In 2016, the company partnered with more than 2,000 organizations for the clinical development of certain products and support for research programs.
Infectious diseases are disorders caused by several pathogenic organisms such as bacteria, viruses, fungi or parasites. These diseases can be transmitted or spread from one person to another through direct contact or indirect contact. Anti-infective drugs are used to treat or prevent these infectious diseases by inhibiting the spread of an infectious agent (static) or by killing the infectious agent (cidal). The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.
Based on the target pathogenic organism, anti-infective drugs are classified as follows –
Antibacterial Drugs/Antibiotic Drugs are used to treat or prevent the bacterial infections. They may kill or inhibit the growth of bacteria.
Antifungal Drugs are used to treat fungal infections.
Antiparasitic Drugs are used to treat infections caused by parasites.
Antiviral Drugs are used to treat viral infections.
Anti-Infective Drugs Market Global is a detailed report giving a unique insight into this market. The report is priced at $4000 for an individual user. To use across your office the price is $6000 and $8000 if you wish to use across a multinational company.
About The Business Research Company
Visit TheBusinessResearchCompany.com, mail info@tbrc.info or call +447443439350 or +918897263534 or +919160996838 for more information on this and many other titles.
The Business Research Company is a market research and intelligence company, which excels in company, market and consumer research.
It has research professionals at its offices in the UK, India and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, chemicals and technology.
The Business Research Company's management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world's largest organizations.